MétaCan
Menu
Back to cohort
Record W4224436935 · doi:10.1186/s13063-022-06085-3

M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID

2022· article· en· W4224436935 on OpenAlexaffabout
Valérie Martel‐Laferrière, Daniel J. Feaster, Lisa R. Metsch, Bruce R. Schackman, Christine Loignon, Bohdan Nosyk, Hansel Tookes, Czarina N. Behrends, Nelson Arruda, Oluleye Adigun, Marie-Ève Goyer, Michael A. Kolber, Jean-Francois Mary, Allan Rodríguez, Iveth G. Yanez, Yue Pan, Rania Khemiri, Lauren Gooden, Aïssata Sako, Julie Bruneau

Bibliographic record

VenueTrials · 2022
Typearticle
Languageen
FieldMedicine
TopicHIV, Drug Use, Sexual Risk
Canadian institutionsSimon Fraser UniversityUniversité de SherbrookeUniversité de MontréalCentre Hospitalier de l’Université de Montréal
FundersNational Institute on Drug AbuseNational Institutes of HealthUniversity of MiamiGilead Sciences
KeywordsMedicinePre-exposure prophylaxisHepatitis CRandomized controlled trialReferralHarm reductionFamily medicineHepatitis C virusHuman immunodeficiency virus (HIV)Internal medicineMen who have sex with menVirologySyphilisVirus

Abstract

fetched live from OpenAlex

BACKGROUND: Opioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID). HIV pre-exposure prophylaxis (PrEP) and HCV treatment regimens have transformative potential to address these co-occurring epidemics. Evaluation of innovative multi-modal approaches, integrating harm reduction, opioid agonist therapy (OAT), PrEP, and HCV treatment is required. The aim of this study is to assess the effectiveness of an on-site integrated care model where delivery of PrEP and HCV treatment for PWID takes places at syringe service programs (SSP) and OAT programs compared with referring PWID to clinical services in the community through a patient navigation model and to examine how structural factors interact with HIV prevention adherence and HCV treatment outcomes. METHODS: HepPrEP) is an open-label, multi-site, multi-center, randomized, controlled, superiority trial with two parallel treatment arms. A total of 500 persons who injected drugs in the prior 6 months and are eligible for PrEP will be recruited in OAT clinics and SSP in Miami, FL, and Montréal, Québec. Participants will be randomized to either on-site care, with adherence counseling, or referral to off-site clinics assisted by a patient navigator. PrEP will be offered to all participants and HCV treatment to those HCV-infected. Co-primary endpoints will be (1) adherence to pre-exposure prophylaxis medication at 6 months post-randomization and (2) HCV sustained virological response (SVR) 12 weeks post-treatment completion among participants who were randomized within the HCV stratum. Up to 100 participants will be invited to participate in a semi-structured interview regarding perceptions of adherence barriers and facilitators, after their 6-month assessment. A simulation model-based cost-effectiveness analysis will be performed to determine the comparative value of the strategies being evaluated. DISCUSSION: The results of this study have the potential to demonstrate the effectiveness and cost-effectiveness of offering PrEP and HCV treatment in healthcare venues frequently attended by PWID. Testing the intervention in two urban centers with high disease burden among PWID, but with different healthcare system dynamics, will increase generalizability of findings. TRIAL REGISTRATION: Clinicaltrials.gov NCT03981445 . Trial registry name: Integrated HIV Prevention and HCV Care for PWID (M2HepPrEP). Registration date: June 10, 201.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.028
metaresearch head score (Gemma)0.023
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.110
Threshold uncertainty score0.368

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0280.023
Meta-epidemiology (narrow)0.0070.003
Meta-epidemiology (broad)0.0090.004
Bibliometrics0.0020.003
Science and technology studies0.0040.004
Scholarly communication0.0040.004
Open science0.0040.002
Research integrity0.0080.008
Insufficient payload (model declined to judge)0.1100.014

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.177
GPT teacher head0.491
Teacher spread0.314 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueTrialsSame topicHIV, Drug Use, Sexual RiskFrench-language works237,207